Anti-Thymocyte Globulin vs Campath-1H vs Daclizumab
ApprovedCompleted 1 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
End-Stage Renal Disease
Conditions
End-Stage Renal Disease, Living Donors
Trial Timeline
Nov 1, 2005 → Dec 1, 2008
NCT ID
NCT01046955About Anti-Thymocyte Globulin vs Campath-1H vs Daclizumab
Anti-Thymocyte Globulin vs Campath-1H vs Daclizumab is a approved stage product being developed by Roche for End-Stage Renal Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01046955. Target conditions include End-Stage Renal Disease, Living Donors.
What happened to similar drugs?
7 of 8 similar drugs in End-Stage Renal Disease were approved
Approved (7) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01046955 | Approved | Completed |
Competing Products
20 competing products in End-Stage Renal Disease